Cardiol Therapeutics wins upgrade from Raymond Jam
Post# of 4861
(Total Views: 251)
Posted On: 04/29/2021 1:45:55 PM
Cardiol Therapeutics wins upgrade from Raymond James
By Jayson MacLean April 28, 2021
With its COVID-19 clinical trial now a go, Cardiol Therapeutics (Cardiol Therapeutics Stock Quote, Chart, News, Analysts, Financials TSX:CRDL) is deserving of a rating boost, says Rahul Sarugaser, analyst for Raymond James. In a report to clients on Wednesday, Sarugaser went from “Market Perform 3” to “Outperform 2” while keeping his $4.25 target price.
Cardiol Therapeutics is a biopharmaceutical company focused on pharmaceutical CBD (cannabidiol) products and on developing therapies for heart disease. The company announced on Wednesday it has enrolled the first patient in its Phase 2/3 trial investigating the cardio-protective properties of CardiolRx, the company’s lead product, an oral CBD formulation.
The LANCER trial is a randomized, double-blind and placebo-controlled study involving 422 hospitalized patients with confirmed diagnosis of COVID-19 and with pre-existing or significant risk factors for cardiovascular disease (CVD). Patients are being enrolled at nine major hospital centres in the US under an Investigational New Drug (IND) application approved by the US FDA.
In the press release, Cardiol said COVID-19 patients primarily present with respiratory symptoms which can progress to bilateral pneumonia and serious pulmonary complications, with patients with pre-existing CVD risk factors are at significant risk of developing CVD complications which are frequently fatal.
“There is compelling evidence that inflammation plays a fundamental role in the development and progression of heart disease,” said Dr. Andrew Hamer, Chief Medical Officer of Cardiol Therapeutics, in the press release. “I am excited to see the initiation of the LANCER trial which will provide a unique opportunity to explore the anti-inflammatory and cardioprotective properties of CardiolRx in COVID-19 patients who are at high risk for major cardiovascular complications.”
https://www.cantechletter.com/2021/04/cardiol...ond-james/
By Jayson MacLean April 28, 2021
With its COVID-19 clinical trial now a go, Cardiol Therapeutics (Cardiol Therapeutics Stock Quote, Chart, News, Analysts, Financials TSX:CRDL) is deserving of a rating boost, says Rahul Sarugaser, analyst for Raymond James. In a report to clients on Wednesday, Sarugaser went from “Market Perform 3” to “Outperform 2” while keeping his $4.25 target price.
Cardiol Therapeutics is a biopharmaceutical company focused on pharmaceutical CBD (cannabidiol) products and on developing therapies for heart disease. The company announced on Wednesday it has enrolled the first patient in its Phase 2/3 trial investigating the cardio-protective properties of CardiolRx, the company’s lead product, an oral CBD formulation.
The LANCER trial is a randomized, double-blind and placebo-controlled study involving 422 hospitalized patients with confirmed diagnosis of COVID-19 and with pre-existing or significant risk factors for cardiovascular disease (CVD). Patients are being enrolled at nine major hospital centres in the US under an Investigational New Drug (IND) application approved by the US FDA.
In the press release, Cardiol said COVID-19 patients primarily present with respiratory symptoms which can progress to bilateral pneumonia and serious pulmonary complications, with patients with pre-existing CVD risk factors are at significant risk of developing CVD complications which are frequently fatal.
“There is compelling evidence that inflammation plays a fundamental role in the development and progression of heart disease,” said Dr. Andrew Hamer, Chief Medical Officer of Cardiol Therapeutics, in the press release. “I am excited to see the initiation of the LANCER trial which will provide a unique opportunity to explore the anti-inflammatory and cardioprotective properties of CardiolRx in COVID-19 patients who are at high risk for major cardiovascular complications.”
https://www.cantechletter.com/2021/04/cardiol...ond-james/
(4)
(0)